Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

Ebola remains a global threat. In a randomized, controlled trial to assess the safety and immunogenicity of two vaccines against Ebola virus disease in Liberia, no safety signals were found. The vaccines elicited immune responses lasting at least 1 year.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-10, Vol.377 (15), p.1438-1447
Hauptverfasser:	Kennedy, Stephen B, Bolay, Fatorma, Kieh, Mark, Grandits, Greg, Badio, Moses, Ballou, Ripley, Eckes, Risa, Feinberg, Mark, Follmann, Dean, Grund, Birgit, Gupta, Swati, Hensley, Lisa, Higgs, Elizabeth, Janosko, Krisztina, Johnson, Melvin, Kateh, Francis, Logue, James, Marchand, Jonathan, Monath, Thomas, Nason, Martha, Nyenswah, Tolbert, Roman, François, Stavale, Eric, Wolfson, Julian, Neaton, James D, Lane, H. Clifford
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoviridae Adenoviruses Adult Allergies Animals Antibody response Clinical trials Disease Outbreaks Disease prevention Double-Blind Method Ebola Vaccines - adverse effects Ebola Vaccines - immunology Ebola virus Ebolavirus Ebolavirus - immunology Epidemics Fatigue Female Fever - etiology Glycoproteins Headache Headache - etiology Hemorrhagic Fever, Ebola - complications Hemorrhagic Fever, Ebola - immunology Hemorrhagic Fever, Ebola - prevention & control HIV Seropositivity - complications Humans Immune response Immunogenicity Infectious diseases Injection Injections, Intramuscular - adverse effects Liberia Male Myalgia - etiology Outbreaks Pain Pan troglodytes Reverse Transcriptase Polymerase Chain Reaction RNA, Viral - blood Stomatitis Vaccines Vesiculovirus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ebola remains a global threat. In a randomized, controlled trial to assess the safety and immunogenicity of two vaccines against Ebola virus disease in Liberia, no safety signals were found. The vaccines elicited immune responses lasting at least 1 year.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1614067